Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in its Fourth Venture Fund
Catalio Capital Management, LP (“Catalio”), a leading innovative healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV (“Fund IV” or the “Fund”), with over $400M in commitments across the Fund and its related co-investment vehicles. The Fund received significant backing from current Catalio investors as well as new, global institutional investors, RIAs, foundations and endowments.
Catalio Capital Management Launches Long-Short Public Equities Strategy Focused on Global Healthcare and Life Sciences Sectors
Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm with more than $1 billion in assets under management, today announced the launch of its dedicated public equities hedge fund investment strategy focused on identifying compelling life science investment opportunities globally. In connection with the launch of the vehicle, the seasoned investment team from HealthCor Management (“HealthCor”), a well-established healthcare hedge fund with a two-decade track record, along with key members of its operations, financial, administrative and marketing divisions, have agreed to join Catalio to help build out the strategy.
Catalio Capital Management Raises Inaugural Special Situations Fund to Provide Creative Financing to Category-defining Healthcare Companies
Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced the successful close of its inaugural special situations fund, Catalio Credit Opportunities Fund I (the “Fund”) with over $85 million in commitments from new and existing institutional investors globally, including leading family offices, endowments, foundations and insurance companies. The fund has made multiple investments in 2022 and looks to capitalize on a robust pipeline of debt and structured equity opportunities during this current market dislocation and beyond.
Chau Khuong Joins Catalio Capital Management as General Partner
Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined the firm as General Partner and Senior Advisor. Mr. Khuong will be based in New York and serve on the Investment Committees of Catalio’s flagship private equity strategy, Nexus, and its Credit Opportunities strategy.
Catalio Capital Management Raises $381 Million for Oversubscribed Third Life Sciences Fund
Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced the successful close of its third venture fund, Catalio Nexus Fund III (“Fund III” or the “Fund”), with more than $381 million in total capital commitments, exceeding its original $300 million target. The Fund received significant backing from current Catalio investors and a number of new, global institutional investors, foundations and endowments.
